Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Nonalcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434–438 (1980).
Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).
Tilg, H. & Moschen, A. R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14, 222–231 (2008).
Maachi, M. et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women. Int. J. Obes. Relat. Metab. Disord. 28, 993–997 (2004).
Targher, G. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30, 2119–2121 (2007).
Targher, G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54, 3541–3546 (2005).
Pais, R. & Bourron, O. Fatty liver and renal function impairment: time for awareness?. J Hepatol. 68, 13–15 (2017).
Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010).
Sumida, Y. & Yoneda, M. Current and future pharmacological therapies for NAFLD/NASH. J. Gastroenterol. 53, 362–376 (2018).
Ghonem, N. S., Assis, D. N. & Boyer, J. L. Fibrates and cholestasis. Hepatology 62, 635–643 (2015).
Montagner, A. et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202–1214 (2016).
Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720–733 (2015).
Chan, S. M. et al. Activation of PPARα ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 62, 2095–2105 (2013).
Souza-Mello, V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J. Hepatol. 7, 1012–1019 (2015).
Choudhary, N. S., Kumar, N. & Duseja, A. Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease. J. Clin. Exp. Hepatol. 9, 731–739 (2019).
Ferretti, A. C. et al. Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration. Sci. Rep. 9, 2815 (2019).
Chaube, B. & Bhat, M. K. AMPK, a key regulator of metabolic/energy homeostasis and mitochondrial biogenesis in cancer cells. Cell Death Dis. 7, e2044 (2016).
Vial, G., Detaille, D. & Guigas, B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne). 10, 294 (2019).
Day, E. A., Ford, R. J. & Steinberg, G. R. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 28, 545–560 (2017).
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
Sag, D., Carling, D., Stout, R. D. & Suttles, J. Adenosine 5’-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181, 8633–8641 (2008).
Yang, L. et al. Effect of AMPK signal pathway on pathogenesis of abdominal aortic aneurysms. Oncotarget. 8, 92827–92840 (2017).
Zhao, P. et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367, 652–660 (2020).
Kheirollahi, V. et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat. Commun. 10, 2987 (2019).
Shankaraiah, R. C. et al. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene 38, 7035–7045 (2019).
Anushiravani, A., Haddadi, N., Pourfarmanbar, M. & Mohammadkarimi, V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. Eur. J. Gastroenterol. Hepatol. 31, 613–617 (2019).
Brackett, C. C. Clarifying metformin’s role and risks in liver dysfunction. J. Am. Pharm. Assoc. 2003(50), 407–410 (2010).
Göke, B., Gause-Nilsson, I. & Persson, A. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab. Vasc. Dis. Res. 4, 204–213 (2007).
Wei, G. et al. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G174–G188 (2020).
Fisher, F. M. et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59, 2781–2789 (2010).
Martin-Montalvo, A. et al. Metformin improves healthspan and lifespan in mice. Nat. Commun. 4, 2192 (2013).
Li, A. C. et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 114, 1564–1576 (2004).
Brunt, E., Janney, C. & Bacon, B. Nonalcoholic Steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94(9), 2467–2474 (1999).
Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366–1374 (2007).
Perry, R. J., Samuel, V. T., Petersen, K. F. & Shulman, G. I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91 (2014).
Rutkowski, D. T. et al. UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev. Cell. 15, 829–840 (2008).
Hotamisligil, G. S. et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271, 665–668 (1996).
Moreno-Fernandez, M. E. et al. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. JCI Insight. 3, e93626 (2018).
Rakhshandehroo, M., Knoch, B., Müller, M. & Kersten, S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. https://doi.org/10.1155/2010/612089 (2010).
Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415–425 (2007).
De Minicis, S. et al. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS ONE 9, e97136 (2014).
Wang, Y. Y. et al. Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. Endocrinology 155, 1235–1246 (2014).
Shibata, T., Takaguri, A., Ichihara, K. & Satoh, K. Inhibition of the TNF-α-induced serine phosphorylation of IRS-1 at 636/639 by AICAR. J. Pharmacol. Sci. 122, 93–102 (2013).
Ueki, K., Kondo, T., Tseng, Y. H. & Kahn, C. R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. 101, 10422–10427 (2004).
Vial, G. et al. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 64, 2254–2264 (2015).
Knight, B. L. et al. A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver. Biochem. J. 389, 413–421 (2005).
DeZwaan-McCabe, D. et al. The stress-regulated transcription factor CHOP promotes hepatic inflammatory gene expression, fibrosis, and oncogenesis. PLoS Genet. 9, e1003937 (2013).
Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
Francque, S. et al. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J. Hepatol. 63, 164–173 (2015).
Dushay, J. et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139, 456–463 (2010).
Xu, X. et al. Preemptive Activation of the Integrated Stress Response Protects Mice From Diet-Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction. Hepatology 68, 2167–2181 (2018).
Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159 (2016).